Диссертация (1140892), страница 23
Текст из файла (страница 23)
417-29.109. Baumgartner C., Cerny-Reiterer S., Sonneck K., Mayerhofer M., Gleixner K. V., Fritz R.,Kerenyi M., Boudot C., Gouilleux F., Kornfeld J. W., Sillaber C., Moriggl R., Valent P.Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellulardistribution and role of the transforming oncoprotein KIT D816V // Am J Pathol.
‒ 2009. ‒ T.175, № 6. ‒ C. 2416-29.110. Soucie E., Hanssens K., Mercher T., Georgin-Lavialle S., Damaj G., Livideanu C., Chandesris M.O., Acin Y., Letard S., de Sepulveda P., Hermine O., Bernard O. A., Dubreuil P. In aggressiveforms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells //Blood.
‒ 2012. ‒ T. 120, № 24. ‒ C. 4846-9.137111. Ko M., Huang Y., Jankowska A. M., Pape U. J., Tahiliani M., Bandukwala H. S., An J., LampertiE. D., Koh K. P., Ganetzky R., Liu X. S., Aravind L., Agarwal S., Maciejewski J. P., Rao A.Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2 // Nature. ‒2010. ‒ T. 468, № 7325. ‒ C. 839-43.112. Tefferi A., Levine R. L., Lim K. H., Abdel-Wahab O., Lasho T.
L., Patel J., Finke C. M., MullallyA., Li C. Y., Pardanani A., Gilliland D. G. Frequent TET2 mutations in systemic mastocytosis:clinical, KITD816V and FIP1L1-PDGFRA correlates // Leukemia. ‒ 2009. ‒ T. 23, № 5. ‒ C.900-4.113. Schwaab J., Schnittger S., Sotlar K., Walz C., Fabarius A., Pfirrmann M., Kohlmann A.,Grossmann V., Meggendorfer M., Horny H. P., Valent P., Jawhar M., Teichmann M.,Metzgeroth G., Erben P., Ernst T., Hochhaus A., Haferlach T., Hofmann W.
K., Cross N. C.,Reiter A. Comprehensive mutational profiling in advanced systemic mastocytosis // Blood. ‒2013. ‒ T. 122, № 14. ‒ C. 2460-6.114. Traina F., Visconte V., Jankowska A. M., Makishima H., O'Keefe C. L., Elson P., Han Y., HsiehF. H., Sekeres M.
A., Mali R. S., Kalaycio M., Lichtin A. E., Advani A. S., Duong H. K.,Copelan E., Kapur R., Olalla Saad S. T., Maciejewski J. P., Tiu R. V. Single nucleotidepolymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present insystemic mastocytosis // PLoS One. ‒ 2012.
‒ T. 7, № 8. ‒ C. e43090.115. Abdel-Wahab O., Adli M., LaFave L. M., Gao J., Hricik T., Shih A. H., Pandey S., Patel J. P.,Chung Y. R., Koche R., Perna F., Zhao X., Taylor J. E., Park C. Y., Carroll M., Melnick A.,Nimer S. D., Jaffe J. D., Aifantis I., Bernstein B. E., Levine R. L. ASXL1 mutations promotemyeloid transformation through loss of PRC2-mediated gene repression // Cancer Cell. ‒ 2012.‒ T. 22, № 2. ‒ C. 180-93.116.
Papaemmanuil E., Gerstung M., Malcovati L., Tauro S., Gundem G., Van Loo P., Yoon C. J.,Ellis P., Wedge D. C., Pellagatti A., Shlien A., Groves M. J., Forbes S. A., Raine K., Hinton J.,Mudie L. J., McLaren S., Hardy C., Latimer C., Della Porta M. G., O'Meara S., Ambaglio I.,Galli A., Butler A. P., Walldin G., Teague J. W., Quek L., Sternberg A., Gambacorti-PasseriniC., Cross N.
C., Green A. R., Boultwood J., Vyas P., Hellstrom-Lindberg E., Bowen D.,Cazzola M., Stratton M. R., Campbell P. J. Clinical and biological implications of drivermutations in myelodysplastic syndromes // Blood. ‒ 2013. ‒ T. 122, № 22. ‒ C. 3616-27; quiz3699.117. Hanssens K., Brenet F., Agopian J., Georgin-Lavialle S., Damaj G., Cabaret L., Chandesris M.O., de Sepulveda P., Hermine O., Dubreuil P., Soucie E. SRSF2-p95 hotspot mutation is138highly associated with advanced forms of mastocytosis and mutations in epigenetic regulatorgenes // Haematologica.
‒ 2014. ‒ T. 99, № 5. ‒ C. 830-5.118. Chan E. C., Bai Y., Bandara G., Simakova O., Brittain E., Scott L., Dyer K. D., Klion A. D.,Maric I., Gilfillan A. M., Metcalfe D. D., Wilson T. M. KIT GNNK splice variants: expressionin systemic mastocytosis and influence on the activating potential of the D816V mutation inmast cells // Exp Hematol. ‒ 2013. ‒ T. 41, № 10.
‒ C. 870-881 e2.119. Schmetzer O., Valentin P., Church M. K., Maurer M., Siebenhaar F. Murine and human mast cellprogenitors // Eur J Pharmacol. ‒ 2016. ‒ T. 778. ‒ C. 2-10.120. Maeda K., Nishiyama C., Tokura T., Akizawa Y., Nishiyama M., Ogawa H., Okumura K., Ra C.Regulation of cell type-specific mouse Fc epsilon RI beta-chain gene expression by GATA-1via four GATA motifs in the promoter // J Immunol.
‒ 2003. ‒ T. 170, № 1. ‒ C. 334-40.121. Nishiyama C., Yokota T., Okumura K., Ra C. The transcription factors Elf-1 and GATA-1 bind tocell-specific enhancer elements of human high-affinity IgE receptor alpha-chain gene // JImmunol. ‒ 1999. ‒ T. 163, № 2. ‒ C. 623-30.122. Babina M., Schulke Y., Kirchhof L., Guhl S., Franke R., Bohm S., Zuberbier T., Henz B. M.,Gombart A. F. The transcription factor profile of human mast cells in comparison withmonocytes and granulocytes // Cell Mol Life Sci. ‒ 2005. ‒ T.
62, № 2. ‒ C. 214-26.123. Lee S. H., Lee J. H., Kim D. K. Involvement of MITF-A, an alternative isoform of mitranscription factor, on the expression of tryptase gene in human mast cells // Exp Mol Med. ‒2010. ‒ T. 42, № 5. ‒ C. 366-75.124. Trimarchi T., Ntziachristos P., Aifantis I. A new player SETs in myeloid malignancy // NatGenet. ‒ 2013.
‒ T. 45, № 8. ‒ C. 846-7.125. Molderings G. J. The genetic basis of mast cell activation disease - looking through a glass darkly// Crit Rev Oncol Hematol. ‒ 2015. ‒ T. 93, № 2. ‒ C. 75-89.126. Orfao A., Garcia-Montero A. C., Sanchez L., Escribano L. Recent advances in the understandingof mastocytosis: the role of KIT mutations // Br J Haematol. ‒ 2007. ‒ T. 138, № 1. ‒ C. 1230.127. Wilson T. M., Maric I., Simakova O., Bai Y., Chan E. C., Olivares N., Carter M., Maric D.,Robyn J., Metcalfe D. D. Clonal analysis of NRAS activating mutations in KIT-D816Vsystemic mastocytosis // Haematologica.
‒ 2011. ‒ T. 96, № 3. ‒ C. 459-63.128. Nedoszytko B., Niedoszytko M., Lange M., van Doormaal J., Glen J., Zablotna M., Renke J.,Vales A., Buljubasic F., Jassem E., Roszkiewicz J., Valent P. Interleukin-13 promoter genepolymorphism -1112C/T is associated with the systemic form of mastocytosis // Allergy. ‒2009. ‒ T. 64, № 2. ‒ C.
287-94.139129. Daley T., Metcalfe D. D., Akin C. Association of the Q576R polymorphism in the interleukin-4receptor alpha chain with indolent mastocytosis limited to the skin // Blood. ‒ 2001. ‒ T. 98,№ 3. ‒ C. 880-2.130. Tefferi A., Lasho T. L., Brockman S. R., Elliott M. A., Dispenzieri A., Pardanani A. FIP1L1PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell diseaseassociated with eosinophilia // Haematologica. ‒ 2004. ‒ T. 89, № 7.
‒ C. 871-3.131. Yamada Y., Cancelas J. A. FIP1L1/PDGFR alpha-associated systemic mastocytosis // Int ArchAllergy Immunol. ‒ 2010. ‒ T. 152 Suppl 1. ‒ C. 101-5.132. Visconte V., Tabarroki A., Rogers H. J., Hasrouni E., Traina F., Makishima H., Hamilton B. K.,Liu Y., O'Keefe C., Lichtin A., Horwitz L., Sekeres M.
A., Hsieh F. H., Tiu R. V. SF3B1mutations are infrequently found in non-myelodysplastic bone marrow failure syndromes andmast cell diseases but, if present, are associated with the ring sideroblast phenotype //Haematologica. ‒ 2013. ‒ T. 98, № 9. ‒ C. e105-7.133. Lange M., Nedoszytko B., Gorska A., Zawrocki A., Sobjanek M., Kozlowski D. Mastocytosis inchildren and adults: clinical disease heterogeneity // Arch Med Sci. ‒ 2012. ‒ T. 8, № 3. ‒ C.533-41.134.
Kuklinski L. F., Kim J. Expression of PD-L1 in mastocytosis // J Am Acad Dermatol. ‒ 2016. ‒T. 74, № 5. ‒ C. 1010-2.135. Kataoka T. R., Fujimoto M., Moriyoshi K., Koyanagi I., Ueshima C., Kono F., Tsuruyama T.,Okayama Y., Ra C., Haga H. PD-1 regulates the growth of human mastocytosis cells //Allergol Int.
‒ 2013. ‒ T. 62, № 1. ‒ C. 99-104.136. Weber A., Knop J., Maurer M. Pattern analysis of human cutaneous mast cell populations by totalbody surface mapping // Br J Dermatol. ‒ 2003. ‒ T. 148, № 2. ‒ C. 224-8.137. Theoharides T. C., Alysandratos K. D., Angelidou A., Delivanis D. A., Sismanopoulos N., ZhangB., Asadi S., Vasiadi M., Weng Z., Miniati A., Kalogeromitros D.
Mast cells and inflammation// Biochim Biophys Acta. ‒ 2012. ‒ T. 1822, № 1. ‒ C. 21-33.138. Metz M., Siebenhaar F., Maurer M. Mast cell functions in the innate skin immune system //Immunobiology. ‒ 2008. ‒ T. 213, № 3-4. ‒ C. 251-60.139. Galli S. J., Nakae S., Tsai M. Mast cells in the development of adaptive immune responses // NatImmunol. ‒ 2005. ‒ T. 6, № 2.
‒ C. 135-42.140. Gilfillan A. M., Tkaczyk C. Integrated signalling pathways for mast-cell activation // Nat RevImmunol. ‒ 2006. ‒ T. 6, № 3. ‒ C. 218-30.141. Mekori Y. A. The mastocyte: the "other" inflammatory cell in immunopathogenesis // J AllergyClin Immunol. ‒ 2004. ‒ T. 114, № 1. ‒ C. 52-7.140142. Metz M., Maurer M. Mast cells--key effector cells in immune responses // Trends Immunol. ‒2007. ‒ T. 28, № 5. ‒ C.
234-41.143. Kawakami T., Galli S. J. Regulation of mast-cell and basophil function and survival by IgE // NatRev Immunol. ‒ 2002. ‒ T. 2, № 10. ‒ C. 773-86.144. Rivera J., Fierro N. A., Olivera A., Suzuki R. New insights on mast cell activation via the highaffinity receptor for IgE // Adv Immunol. ‒ 2008. ‒ T. 98. ‒ C. 85-120.145.
Theoharides T. C., Petra A. I., Stewart J. M., Tsilioni I., Panagiotidou S., Akin C. High serumcorticotropin-releasing hormone (CRH) and bone marrow mast cell CRH receptor expressionin a mastocytosis patient // J Allergy Clin Immunol. ‒ 2014. ‒ T. 134, № 5. ‒ C. 1197-9.146. Puri N., Roche P.
A. Mast cells possess distinct secretory granule subsets whose exocytosis isregulated by different SNARE isoforms // Proc Natl Acad Sci U S A. ‒ 2008. ‒ T. 105, № 7. ‒C. 2580-5.147. Wasiuk A., de Vries V. C., Hartmann K., Roers A., Noelle R. J. Mast cells as regulators ofadaptive immunity to tumours // Clin Exp Immunol. ‒ 2009. ‒ T. 155, № 2. ‒ C. 140-6.148. Voehringer D. Protective and pathological roles of mast cells and basophils // Nat Rev Immunol.‒ 2013. ‒ T.
13, № 5. ‒ C. 362-75.149. Valent P., Akin C., Arock M., Brockow K., Butterfield J. H., Carter M. C., Castells M., EscribanoL., Hartmann K., Lieberman P., Nedoszytko B., Orfao A., Schwartz L. B., Sotlar K., Sperr W.R., Triggiani M., Valenta R., Horny H. P., Metcalfe D. D. Definitions, criteria and globalclassification of mast cell disorders with special reference to mast cell activation syndromes: aconsensus proposal // Int Arch Allergy Immunol. ‒ 2012. ‒ T.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
